

Special Issue

Evolving Concepts on Novel Targeted Therapies in the Treatment of Multiple Myeloma

Message from the Guest Editors

Multiple myeloma (MM) is characterized by the uncontrollable proliferation of plasma cells and the excessive production of a specific type of immunoglobulin. The immune system is deregulated in MM and, thus, targeted treatments which aim to restore immune function are a promising therapeutic strategy. Antibody therapy has significantly enhanced the armamentarium against MM. Further research should focus on tailoring the combination regimens based on disease and patient characteristics in order to optimize the efficacy and safety. Another aspect is the role of minimal residual disease, which aims to guide therapeutic decisions with novel targeted agents. Lastly, the cost-effectiveness of novel agents has to be taken into consideration, and the best means of determining the optimal clinical benefit according to the anticipated cost of treatment remains elusive. This Special Issue will address the most recent and relevant scientific findings regarding the evolving concepts and challenges in novel targeted therapies in the treatment of MM.

Guest Editors

Dr. Ioannis Ntanasis-Stathopoulos

Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece

Prof. Dr. Evangelos Terpos

Department of Clinical Therapeutics, School of Medicine, University of Athens, Athens, Greece

Deadline for manuscript submissions

closed (25 March 2022)



Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 5.7
Indexed in PubMed



mdpi.com/si/60937

Journal of Clinical Medicine
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jcm@mdpi.com

mdpi.com/journal/

jcm





Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 5.7
Indexed in PubMed



mdpi.com/journal/

[jcm](https://jcm.mdpi.com/)



About the Journal

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Editors-in-Chief

Prof. Dr. Emmanuel Andrès

Internal Medicine Department, University Hospital Strasbourg, 67000
Strasbourg, France

Prof. Dr. Kent Doi

Department of Acute Care Medicine, University of Tokyo, Tokyo, Japan

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1
(General Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.3 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2024).